Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 2/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.40 |
| ▸ | PYGM | P11217 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933232 | 0.83 | ALDH1A1 (0.41) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL67327 | 0.82 | LMNA (0.47) | LMNA | |
| SCHEMBL932885 | 0.82 | ALDH1A1 (0.40) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL66481 | 0.82 | LMNA (0.41) | LMNATK2 | |
| Ammonia Solution, Strong SCHEMBL2469221 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL8422445 | 0.74 | LMNA (0.52) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL8422441 | 0.74 | LMNA (0.52) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL15164434 | 0.74 | LMNA (0.50) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL11404005 | 0.73 | DNPH1 (0.45) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL932061 | 0.73 | LMNA (0.43) | ALDH1A1LMNAALBPOLBADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139911-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| EP-1855694-B1 | ANTISENSE COMPOSITION FOR TREATING MUSCLE ATROPHY | SAREPTA THERAPEUTICS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10626396-B2 | Antisense composition and method for treating muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10479996-B2 | Antisense antiviral compound and method for treating ss/RNA viral infection | SAREPTA THERAPEUTICS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180327749-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-11-15 | — | — | US | disclosed |
| US-10006031-B2 | Antisense composition and method for treating muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-9982261-B2 | Antisense antiviral compounds and methods for treating a filovirus infection | SAREPTA THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170306323-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-10-26 | — | — | US | disclosed |
| EP-3205342-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | Sarepta Therapeutics, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2603220-B1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | SAREPTA THERAPEUTICS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-1654363-A2 | OLIGONUCLEOTIDE ANALOG AND METHOD FOR TREATING FLAVIVIRUS INFECTIONS | Avi Biopharma, Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006047683-A2 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING INFLUENZA VIRAL INFECTION | AVI BIOPHARMA, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006033933-A2 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING SSRNA VIRAL INFECTION | AVI BIOPHARMA, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063150-A1 | Antisense antiviral compound and method for treating ssRNA viral infection | SAREPTA THERAPEUTICS, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20050261249-A1 | Antisense composition and method for treating cancer | AVI BIOPHARMA, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005089247-A2 | ANTISENSE COMPOSITION AND METHOD FOR TREATING CANCER | AVI BIOPHARMA, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050171044-A1 | Oligonucleotide compound and method for treating nidovirus infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-04 | — | — | US | disclosed |
| WO-2005065268-A2 | OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING NIDOVIRUS INFECTIONS | AVI BIOPHARMA, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050096291-A1 | Oligonucleotide analog and method for treating flavivirus infections | SAREPTA THERAPEUTICS, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005030800-A2 | OLIGONUCLEOTIDE ANALOG AND METHOD FOR TREATING FLAVIVIRUS INFECTIONS | AVI BIOPHARMA, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170306323-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | HNRNPU, MED25, SSU72 | ALDH1A1 4570/4885LMNA 1275/4885ALB 2863/4885 |
| US-20050171044-A1 | Oligonucleotide compound and method for treating nidovirus infections | RNGTT, NSUN2, FBL | ALDH1A1 4822/4885LMNA 806/4885ALB 3428/4885 |
| US-10006031-B2 | Antisense composition and method for treating muscle atrophy | MYOF, TNNC1, MTPN | ALDH1A1 4879/4885LMNA 549/4885ALB 2496/4885 |
| US-10479996-B2 | Antisense antiviral compound and method for treating ss/RNA viral infection | SARS1, SSU72, RNGTT | ALDH1A1 3964/4885LMNA 2372/4885ALB 2680/4885 |
| US-10626396-B2 | Antisense composition and method for treating muscle atrophy | MYOF, TNNC1, MTPN | ALDH1A1 4879/4885LMNA 549/4885ALB 2496/4885 |
| US-20180327749-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | MYOF, TNNC1, MTPN | ALDH1A1 4879/4885LMNA 549/4885ALB 2496/4885 |
| US-20060063150-A1 | Antisense antiviral compound and method for treating ssRNA viral infection | SARS1, RNGTT, EIF2AK2 | ALDH1A1 3030/4885LMNA 1351/4885ALB 2000/4885 |
| US-20210139911-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | MYOF, TNNC1, MTPN | ALDH1A1 4879/4885LMNA 549/4885ALB 2496/4885 |
| US-20050096291-A1 | Oligonucleotide analog and method for treating flavivirus infections | NSUN2, RNGTT, ADAR | ALDH1A1 4415/4885LMNA 357/4885ALB 4314/4885 |
| US-20050261249-A1 | Antisense composition and method for treating cancer | RNASE1, HNRNPH3, HNRNPD | ALDH1A1 2855/4885LMNA 622/4885ALB 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.